Based on the Intellia Therapeutics Inc stock forecast from 9 analysts, the average analyst target price for Intellia Therapeutics Inc is USD 50.86 over the next 12 months. Intellia Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Intellia Therapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Intellia Therapeutics Inc’s stock price was USD 16.00. Intellia Therapeutics Inc’s stock price has changed by +12.52% over the past week, -10.31% over the past month and -45.74% over the last year.
No recent analyst target price found for Intellia Therapeutics Inc
No recent average analyst rating found for Intellia Therapeutics Inc
Company Overview Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Read Less
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of heredita...Read More
Frequently Asked Questions About Intellia Therapeutics Inc (NTLA) Stock
Based on ratings from 9 analysts Intellia Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 11 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on NTLA's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for NTLA is USD 50.86 over the next 12 months. The maximum analyst target price is USD 73 while the minimum anlayst target price is USD 19.
NTLA stock's Price/Earning ratio is 115.00.
Our analysis grades NTLA stock's Price / Earning ratio at F. This means that NTLA stock's Price/Earning ratio is above 90% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this NTLA may be a overvalued for its sector.
The last closing price of NTLA's stock was USD 16.00.
The most recent market capitalization for NTLA is USD 1.45B.
Based on targets from 9 analysts, the average taret price for NTLA is projected at USD 50.86 over the next 12 months.
This means that NTLA's stock price may go up by +217.86% over the next 12 months.
We can't find any ETFs which contains Intellia Therapeutics Inc's stock.
As per our most recent records Intellia Therapeutics Inc has 526 Employees.
Intellia Therapeutics Inc's registered address is 40 Erie Street, Cambridge, MA, United States, 02139.
You can get more information about it from Intellia Therapeutics Inc's website at https://www.intelliatx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Intellia Therapeutics Inc (NTLA) Stock
Based on ratings from 9 analysts Intellia Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 11 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on NTLA's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for NTLA is USD 50.86 over the next 12 months. The maximum analyst target price is USD 73 while the minimum anlayst target price is USD 19.
NTLA stock's Price/Earning ratio is 115.00.
Our analysis grades NTLA stock's Price / Earning ratio at F. This means that NTLA stock's Price/Earning ratio is above 90% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this NTLA may be a overvalued for its sector.
The last closing price of NTLA's stock was USD 16.00.
The most recent market capitalization for NTLA is USD 1.45B.
Based on targets from 9 analysts, the average taret price for NTLA is projected at USD 50.86 over the next 12 months.
This means that NTLA's stock price may go up by +217.86% over the next 12 months.
We can't find any ETFs which contains Intellia Therapeutics Inc's stock.
As per our most recent records Intellia Therapeutics Inc has 526 Employees.
Intellia Therapeutics Inc's registered address is 40 Erie Street, Cambridge, MA, United States, 02139.
You can get more information about it from Intellia Therapeutics Inc's website at https://www.intelliatx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NTLA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
